´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ 2022³â Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-11-18 |
|
´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ 2022³â Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-11-18 ±³À°ÀÏÀÚ : 2022-11-18 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ & ´ëȸÀÇ½Ç ±³À°ÁÖÁ¦ : ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ 2022³â Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° ÁÖÃÖ±â°ü : ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ ´ã´çÀÚ : ±èÈ«ÀÎ ¿¬¶ôó : 02-6203-2595 À̸ÞÀÏ : kagp@hanmail.net ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú, ½Å°æ°ú Âü¼®¿¹»óÀοø : 400¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 11 ½Ã°£ 25ºÐ ¼¼ºÎ¼ö°·á : 60,000¿ø ºñ°í * µî·Ïºñ(»çÀüµî·Ï) Á¤È¸¿ø Àü¹®ÀÇ 4¸¸¿ø, ºñȸ¿ø Àü¹®°¡ 5¸¸¿ø, ÀÎÁõÀÇ. ¼ö·Ã»ý. ¿¬±¸¿ø µî 3¸¸¿ø (ÇöÀåµî·Ï) »çÀüµî·Ïºñ +1¸¸¿ø, Æò»ýȸ¿øÀº ¸éÁ¦ * Çмú´ëȸ ÄÁº¥¼ÇȦ, ¿¬¼ö±³À° ´ëȸÀǽǿ¡¼ µ¿½Ã ÁøÇà ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 09:10~09:30 Amyloid Cascade Hypothesis ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 09:30~09:50 Hyperphosphorylated Tau Hypothesis À̵¿¿µ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 09:50~10:10 Inflammatory Hypothesis ±èÁØÇü(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 10:10~10:30 Mitochondrial Cascade Hypothesis ½ÅÀϼ±(Àü³²ÀÇ´ë) Åä·Ð 11-18 ÄÁº¥¼ÇȦ 10:30~10:40 Q & A () ÈÞ½Ä 11-18 ÄÁº¥¼ÇȦ 10:40~11:00 Coffee Break () ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ & ´ëȸÀÇ½Ç 11:00~11:40 ±¹³» Ä¡¸Å±Øº¹¿¬±¸°³¹ßÀÇ ÃÖ½ÅÁö°ß ¹¬ÀÎÈñ(¼¿ïÀÇ´ë »ýÈÇб³½Ç) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ & ´ëȸÀÇ½Ç 11:40~12:20 Diagnosis and Treatment of Alzheimer¡¯s Disease: Lessons from the Alzheimer¡¯s Disease Neuroimaging Initiative (ADNI) Michael Weiner(UCSF PI of ADNI) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 12:20~13:00 Á¤½Å°ú¿¡¼ º¸´Â Ä¡¸Å´Â ¹«¾ùÀ» °í·ÁÇؾßÇϴ°¡? ¼Õ»óÁØ(¾ÆÁÖÀÇ´ë) ÈÞ½Ä 11-18 ÄÁº¥¼ÇȦ & ´ëȸÀÇ½Ç 13:00~13:30 poster ½É»ç ¹× ÈÞ½Ä () ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 13:30~13:50 Hyperlipidemia: Statins Á¤¼ö¹Î(¼¿ïÀÇ´ë °¡Á¤ÀÇÇаú) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 13:50~14:10 Depression: Antidepressants ±èÇöÁ¤(Áß¾Ó´ë ¾àÇаú) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 14:10~14:30 DM: Thiazolidinedione and GLP-1 agonists ±è¿øÁØ(¿ï»êÀÇ´ë ³»°ú) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 14:30~14:50 SVD: Phosphodiesterase inhibitors ÀÌÁØ¿µ(¼¿ïÀÇ´ë) Åä·Ð 11-18 ÄÁº¥¼ÇȦ 14:50~15:00 Q & A () ÈÞ½Ä 11-18 ÄÁº¥¼ÇȦ 15:00~15:20 Coffee break () ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 15:20~15:45 µðÁöÅÐ ½Å°æ½É¸®°Ë»ç ÁøÁÖÈñ(»ï¼º¼¿ïº´¿ø ½Å°æ°ú) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 15:45~16:10 µðÁöÅÐ ¿ä¾ç ÀÌÁø¿(Çѱ¹½Ã´Ï¾î¿¬±¸¼Ò) ±³À°½Ã°£ 11-18 ÄÁº¥¼ÇȦ 16:10~16:35 AI ³ú¿µ»ó ºÐ¼® ÀÌÀ缺(¼¿ïÀÇ´ë ÇÙÀÇÇаú) Åä·Ð 11-18 ÄÁº¥¼ÇȦ 16:35~16:50 Q & A () ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 09:10~09:35 ³ë³â±â ³ú°Ç°À» À§ÇÑ ¿µ¾ç°ü¸® ¹ÚÀ¯°æ(°æÈñ´ë ÀÇÇпµ¾çÇаú) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 09:35~10:00 ³ë³â±â ³ú°Ç°À» À§ÇÑ ¿îµ¿¿ä¹ý ¼ÛÈ«¼±(Çѱ¹½ºÆ÷Ã÷Á¤Ã¥°úÇпø) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 10:00~10:25 ³ë³â±â ³ú°Ç°À» À§ÇÑ ºñŸ¹Î ¹× º¸ÃæÁ¦ À±¼¿µ(´ë±¸°¡Å縯ÀÇ´ë) Åä·Ð 11-18 ´ëȸÀÇ½Ç 10:25~10:40 Q & A () ÈÞ½Ä 11-18 ´ëȸÀÇ½Ç 10:40~11:00 Coffee break () ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 12:20~13:00 Zyprexa's New Role and Benefit in the Psychiatric Field - Focus on Geriatric Psychiatry ÃßÀÏÇÑ(Á¶¼±ÀÇ´ë) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 13:30~13:50 Ä¡¸Å ȯÀÚÀÇ ¿îµ¿Àå¾Ö ´ëó (Management of movement disorder in dementia patient) ±Çµµ¿µ(°í·ÁÀÇ´ë ½Å°æ°ú) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 13:50~14:10 Ä¡¸Å ȯÀÚÀÇ ÀϸôÁõÈıº ´ëó (Management of sundowning syndrome in dementia patient) °µ¿¿ì(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 14:10~14:30 Ä¡¸Å ȯÀÚÀÇ ºÎÀûÀýÇÑ ¼ºÀû Çൿ ´ëó (Management of inappropriate sexual behavior in dementia patient) ½Åö¹Î(°í·ÁÀÇ´ë) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 14:30~14:50 Ä¡¸Å ȯÀÚÀÇ ÅëÁõ ´ëó (Management of pain in dementia patient) °¿ø¼·(°æÈñÀÇ´ë) Åä·Ð 11-18 ´ëȸÀÇ½Ç 14:50~15:00 Q & A () ÈÞ½Ä 11-18 ´ëȸÀÇ½Ç 15:00~15:20 Coffee Break () ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 15:20~15:45 ¾ËÃ÷ÇÏÀÌ¸Ó Ä¡¸Å ȯÀÚ¿¡¼ MRI º¸±â ³ëÇö¿õ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 15:45~16:10 Ç÷°ü¼º Ä¡¸Å ȯÀÚ¿¡¼ MRI º¸±â À̹οì(ÇѸ²ÀÇ´ë ½Å°æ°ú) ±³À°½Ã°£ 11-18 ´ëȸÀÇ½Ç 16:10~16:35 Ä¡¸Å ȯÀÚ¿¡¼ PET º¸±â ÇϽ±Õ(°¡Å縯ÀÇ´ë ÇÙÀÇÇаú) ÈÞ½Ä 11-18 ´ëȸÀÇ½Ç 16:35~16:50 Q & A () |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|